Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Transplant. 2013 Oct;13(10):2730-3. doi: 10.1111/ajt.12391. Epub 2013 Aug 5.

Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.

Author information

1
Department of Cardiology, Advanced Heart Failure and Transplantation, Texas Heart Institute, Houston, TX.

Abstract

We describe a patient who underwent a successful heart and kidney transplant for light-chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow-up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode.

KEYWORDS:

Allograft rejection; amyloidosis; cardiac transplant; lenalidomide; renal transplant; transplantation

PMID:
23914832
DOI:
10.1111/ajt.12391
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center